Nefrotoxicidade da Cisplatina

• Autor(a) principal: Broecker Neto, Adalberto
• Data de Publicação: 2023
• Outros Autores: Lago, Sérgio, Radke, Rodolfo Coutinho, Costa, Ailzo José da, Kalil, Nelson Gustavo M.
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3265
• topic: Cisplatina; Nefrotoxicidade; Quimioterapia; Terapêutica Antineoplásica; Cisplatinum; Nephrotoxicity; Chemotherapy; Antineoplasic Therapy

Two hundred and ninety two patients were treated wíth 1.106 courses of Cisplatinum (DDP) with nephrotoxicity of 9.7% (7.9% mild, 1.6% moderate and 0,2% severe). Two hundred and three patientes (757 courses) were treated in an outpatient regímen and the DDP was given without previous hydration and in a three-hour infusion schedule. The renal toxicity observed in this group was 10. 1% (8.4% mild, 1.4% moderate and 0.2% severe). All patients were studied according to the presence of previous renal function abnormalities, methods of drug administration, primary tumor sites, dosage per course, schedule of DDP administration and cumulatives doses. The presence of previous renal function abnormalities was found to be the most important factor in developing nephrotoxicity with the use of DDP (P <a 0001). No relationship was found between nephrotoxicity and the method of DDP administration, primary tumor sites, dosis given per courses, schedule of administration and cumulatíve doses. The administration of DDP on an outpatient regimen with no previous hydration is safe and with acceptable renal toxicíty.